DNDi is also working with partners on two new chemical entities for this disease: oxaborole SCYX-7158 and fexinidazole. The first is an oral compound which is currently concluding Phase I clinical studies, while fexinidazole, also an oral treatment, began Phase II/III studies in the Democratic Republic of the Congo and Central African Republic in October 2012.
"A safe, effective, oral-only treatment would simplify the way the disease is managed," Pcoul explains, "as well as supporting the WHO's target to eliminate sleeping sickness by 2020."
Leishmaniasis and Chagas
DNDi is also about to start Phase II studies testing efficacy and safety on the use of fexinidazole in visceral leishmaniasis patients in East Africa.
Ten years ago, the standard treatment for visceral leishmaniasis was a month-long course of painful daily injections, a treatment schedule that is difficult to manage in poorly equipped health centers in the remote areas where the disease is found. The combined therapy delivered by DNDi has already shortened the treatment duration to 17 days, but the goal remains to come up with an oral treatment.
In the case of Chagas disease, a decade ago there were no pediatric formulations. DNDi's dosage form for children up to the age of two is oral, inexpensive, and easy-to-use. It is also designed for home administration: an important pro-compliance factor in what is a lengthy two-month treatment.
Another oral drug, E1224, is currently being tested on adult patients in Bolivia. "If successful," Pcoul says, "this drug could be the oral, easy-to-use, affordable and safe treatment option that Chagas patients need and deserve."
These ongoing projects are joined by an early-stage pipeline of twelve entirely new chemical entities.'/>"/>
|Contact: Violaine Dällenbach|
Drugs for Neglected Diseases Initiative